Form 4 for TARS Tarsus Pharmaceuticals, Inc.
Accepted 2022-12-01 00:00:00 ET · period of report 2022-11-29 · accession 0001839516-22-000004 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2022-12-01 | 2022-11-30+ | TARS | Whitfield Dianne C. | CHRO | S - Sale+OE | $16.62 | -2,347 | 9,877 | -19% | -$39.0K |
| D | 2022-12-01 | 2022-11-29 | TARS | Whitfield Dianne C. | CHRO | M - OptEx | $0.00 | +10.3K | 12.2K | +520% | $0 |
| D | 2022-12-01 | 2022-11-29 | TARS | Whitfield Dianne C. | CHRO | M - OptEx | $0.00 | -10.3K | 23.9K | -30% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-11-30 | S | D | 1,182 | $16.50 | 11,042 | D | — | — | (F3) The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. |
| 2 | Common | Common Stock | 2022-12-01 | S | D | 1,165 | $16.75 | 9,877 | D | — | — | (F3) The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. |
| 3 | Common | Common Stock | 2022-11-29 | M | A | 10,251 | $0.00 | 12,224 | D | — | — | (F2) Includes 862 shares acquired under the Issuer's employee stock purchase plan on December 31, 2021, and includes 1,111 shares acquired under the Issuer's employee stock purchase plan on June 30, 2022. |
| 4 | Derivative | Restricted Stock Units | 2022-11-29 | M | D | 10,251 | $0.00 | 23,920 | D | — · — to — | 10,251 Common Stock | (F4) RSU granted under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. The RSUs will vest 30% on November 29, 2022, and 70% on November 29, 2023, subject to the Reporting Person's continuous service. |